NHS NEL
Demonstration Formulary
6 Endocrine system
06-04-01-01 Oestrogens and HRT
Evorel Conti
®
First Choice
Evorel Sequi
®
First Choice
Evorel®
First Choice
Femseven Conti®
Second Choice
Femseven Sequi®
Second Choice
2nd line to Evorel Sequi®
COMBINED CYCLICAL HRT
Formulary
BRANDS
Elleste-Duet
Prempak-C
Elleste Solo
Formulary
Elleste-Duet Conti®
Formulary
Clinorette®
Formulary
Estraderm MX®
Formulary
Estradot®
Formulary
Estriol® 0.01%
Formulary
Femseven ®
Formulary
Kliofem
®
Formulary
Kliovance
®
Formulary
Lubion®
Formulary
Fertility use only
Novofem®
Formulary
Ovestin ®
Formulary
Premarin®
Formulary
Premique® low dose
Formulary
Tridestra®
Formulary
Zumenon®
Formulary
Indivina®
Formulary
Premique® modified release
Formulary
Progynova
®
Formulary
Progynova® 1mg and 2mg tablets
Climanor
®
Formulary
Bazedoxifene/Conjugated Oestrogens
Duavive
®
Non Formulary
BMS- guidance on HRT prescribing
Climagest
Non Formulary
Climaval
®
Non Formulary
Cyclo-Progynova
®
Non Formulary
Estradiol with progesterone continuous tablets for HRT
Angeliq
®
Non Formulary
Hormonin
®
Non Formulary
Nuvelle Continous tablets
Non Formulary
Primolut N
®
Non Formulary
Utrogestan
®
Vaginal Capsules
Non Formulary
Links
Advice on prescribing HRT products during issues with supply - May 2022
Advice on prescribing HRT products during issues with supply - May 2022
Advice on prescribing HRT products during issues with supply - May 2022
Advice on prescribing HRT products during issues with supply - May 2022
Advice on prescribing HRT products during issues with supply - May 2022
Advice on prescribing HRT products during issues with supply - May 2022
Advice on prescribing HRT products during issues with supply - May 2022
Advice on prescribing HRT products during issues with supply - May 2022
Advice on prescribing HRT products during issues with supply - May 2022
BMS- guidance on HRT prescribing
BMS- guidance on HRT prescribing
Clinical Knowledge Summary - Menopause
DVLA guidance
NICE Guidance on prescribing
NICE NG28: Type 2 diabetes in adults: management
NICE TA 160 Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Key
Full Site